Abstract
We propose a new approach to estimate the vaccination rates required to achieve herd immunity against SARS-COV2 virus at a city level. Based on information obtained from the Israeli Ministry of Health, we estimate two separate quadratic models, one for each dose of the BNT162b2 mRNA Pfizer vaccine. The dependent variable is the scope of morbidity, expressed as the number of cases per 10,000 persons. The independent variables are the first and second vaccination rates and their squares. The outcomes corroborate that herd immunity is achieved in the case that 71 percent of the urban population is vaccinated, and the minimum anticipated scope of morbidity is approximately 5 active COVID-19 cases per 10,000 persons, compared to 53–67 cases per 10,000 persons for zero vaccination rate. Findings emphasize the importance of vaccinations and demonstrate that urban herd immunity may be defined as a situation in which people continue to interact, yet the COVID-19 spread is contained. This, in turn, might prevent the need for lockdowns or other limitations at the city level.
Publisher
Public Library of Science (PLoS)
Reference15 articles.
1. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting;N Dagan;The New England journal of medicine,2021
2. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic;V. J. Clemente-Suárez;Vaccines,2020
3. Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States;H. Kalish;Science translational medicine,2021
4. Rethinking Herd Immunity: Managing the Covid-19 Pandemic in a Dynamic Biological and Behavioral Environment;Pierre Barker;NEJM Catalyst,2021
5. Burden and characteristics of COVID-19 in the United States during 2020;S Pei;Nature,2021